MODIFIED RNA ENCODING VEGF-A POLYPEPTIDES, COMPOSITIONS CONTAINING IT, AND THEIR APPLICATION METHODS Russian patent published in 2021 - IPC A61K31/7088 A61K38/18 A61K47/02 A61K48/00 C07K14/475 C07K14/52 A61P9/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology, specifically to pharmaceutical compositions of modified RNA molecules encoding VEGF-A; it can be used in medicine for VEGF-A therapy. A composition is proposed for the delivery of modified mRNA encoding VEGF-A polypeptide in vivo during VEGF-A therapy, containing effective amount of mRNA encoding VEGF-A polypeptide and a citrate-salt buffer, where the citrate-salt buffer practically does not contain divalent cations. The composition is used in a method for the treatment of a disease that demonstrates an improvement in one or several symptoms or clinical markers after VEGF-A therapy, for example, a disease selected from heart failure with a reduced or preserved ejection fraction, cardiac dysfunction after MI, ischemic heart disease and skin ulcers, including diabetic ulcers.

EFFECT: invention provides a reduction in the toxicity of the composition for the delivery of modified mRNA encoding VEGF-A in vivo.

13 cl, 52 dwg, 2 tbl, 19 ex